Fierce Biotech

FDA places Intellia phase 3 CRISPR trials on hold over raised liver enzymes

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...
Zacks Investment Research on MSN

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Biotechnology is strutting on the runway

The apparel industry accounts for 10% of greenhouse gas emissions. Biotechs are working on reengineering natural products to make more sustainable textiles, which are gaining traction.

CRISPR Crisis: Intellia Stock Crashes 40% After Shock Trial Pause

A hospitalized patient triggers a major setback for Intellia's $1.9B flagship drug, shaking investor faith overnight ...
Zacks Investment Research on MSN

CRISPR Therapeutics AG (CRSP) Stock Moves -2.51%: What You Should Know

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $62.56, moving -2.51% from the previous trading session. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq ...